Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica)

American Journal of Hematology

Volumn 87, Issue 2, 2012, Pages 238-243

  Fioredda, Francesca ^a   Calvillo, Michaela ^a   Bonanomi, Sonia ^b   Coliva, Tiziana ^b   Tucci, Fabio ^c   Farruggia, Piero ^d   Pillon, Marta ^e   Martire, Baldassarre ^f   Ghilardi, Roberta ^g   Ramenghi, Ugo ^h   Renga, Daniela ⁱ   Menna, Giuseppe ^j   Pusiol, Anna ^j   Barone, Angelica ^k   Gambineri, Eleonora ^c   Palazzi, Giovanni ^l   Casazza, Gabriella ^m   Lanciotti, Marina ^a   Dufour, Carlo ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d G di Cristina Children Hospital   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^h REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

ⁱ Pausillipon Hospital   (Italy)

^j UNIVERSITY OF UDINE   (Italy)

^k UNIVERSITY HOSPITAL OF PARMA   (Italy)

^l UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^m UNIVERSITY OF PISA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACQUIRED NEUTROPENIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOIMMUNE NEUTROPENIA; BONE MARROW TRANSPLANTATION; CONGENITAL NEUTROPENIA; CONTROLLED STUDY; DRUG DOSE INCREASE; FOLLOW UP; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE 1B; HUMAN; IDIOPATHIC NEUTROPENIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; SEVERE CONGENITAL NEUTROPENIA; SHWACHMAN SYNDROME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE MARROW TRANSPLANTATION; CHILD; CONSENSUS; DISEASE MANAGEMENT; DRUG ADMINISTRATION SCHEDULE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEUTROPENIA; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855951235     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22242     Document Type: Article

References (59)

1. Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br J Haematol 2002; 116: 28-56.
2. Zeidler C, Boxer L, Dale DC, et al. Management of Kostmann syndrome in the G-CSF era. Br J Haematol 2000; 2: 490-495.
3. Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. Semin Hematol 2006; 43: 189-195.
4. Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003; 72: 82-93.
5. Freedman MH, Bonilla MA, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000; 96: 429-36.
6. Rosenberg PS, Alter BP, Link DC, et al. Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol 2008; 140: 210-213.
7. Beekman R, Touw IP. G-CSF and its receptor in myeloid malignancy. Blood 2010; 115: 5131-5136.
8. De MD, Del PD, Del Vecchio GC, et al. Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Associazione Italiana di Ematologia e Oncologia Pediatrica. Haematologica 2000; 85: 420-424.
9. Fioredda F, Calvillo M, Bonanomi S, et al. Congenital and acquired neutropenia consensus guidelines on diagnosis from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). Pediatr Blood Cancer 2011; 57: 10-17.
10. Spiekermann K, Roesler J, Emmendoerffer A, et al. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: Differential effects and clinical implications. Leukemia 1997; 11: 466-478.
11. Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF): The first 10 years. Blood 1996; 88: 1907-1929.
12. Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81: 2496-2502.
13. Zeidler C, Welte K. Kostmann syndrome and severe congenital neutropenia. Semin Hematol 2002; 39: 82-88.
14. Carlsson G, Fasth A. Infantile genetic agranulocytosis, morbus Kostmann: Presentation of six cases from the original "Kostmann family" and a review. Acta Paediatr 2001; 90: 757-764.
15. Rosenberg PS, Zeidler C, Bolyard AA, et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol 2010; 150: 196-199.
16. Carlsson G, Ahlin A, Dahllof G, et al. Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia. Br J Haematol 2004; 126: 127-132.
17. Choi LM, Guelcher C, Guerrera MF. Novel treatment for severe congenital neutropenia with pegfilgrastim. Blood 2007; 110: 4134.
18. Lahteenmaki PM, Jahnukainen K, Pelliniemi TT, et al. Severe congenital neutropenia and pegfilgrastim. Eur J Haematol 2009; 82: 75-76.
19. Beaupain B, Leblanc T, Reman O, et al. Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry. Pediatr Blood Cancer 2009; 53: 1068-1073.
20. Fioredda F, Calvillo M, Lanciotti M, et al. Pegfilgrastim in children with severe congenital neutropenia. Pediatr Blood Cancer 2010; 54: 465-467.
21. Berliner N, Horwitz M, Loughran TPJr. Congenital and acquired neutropenia. Hematology Am Soc Hematol Educ Program 2004; 63-79.
22. Palmblad JE, von dem Borne AE. Idiopathic, immune, infectious, and idiosyncratic neutropenias. Semin Hematol 2002; 39: 113-120.
23. Smith MA, Smith JG. The use of granulocyte colony-stimulating factor for treatment of autoimmune neutropenia. Curr Opin Hematol 2001; 8: 165-169.
24. Bux J, Behrens G, Jaeger G, Welte K. Diagnosis and clinical course of autoimmune neutropenia in infancy: Analysis of 240 cases. Blood 1998; 91: 181-186.
25. Donadieu J, Leblanc T, Bader MB, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica 2005; 90: 45-53.
26. Dale DC, Bolyard AA, Aprikyan A. Cyclic neutropenia. Semin Hematol 2002; 39: 89-94.
27. Jayabose S, Tugal O, Sandoval C, Li K. Recombinant human granulocyte colony stimulating factor in cyclic neutropenia: Use of a new 3-day-a-week regimen. Am J Pediatr Hematol Oncol 1994; 16: 338-340.
28. Calderwood S, Kilpatrick L, Douglas SD, et al. Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. Blood 2001; 97: 376-382.
29. Pinsk M, Burzynski J, Yhap M, et al. Acute myelogenous leukemia and glycogen storage disease 1b. J Pediatr Hematol Oncol 2002; 24: 756-758.
30. Schroeder T, Hildebrandt B, Mayatepek E, et al. A patient with glycogen storage disease type Ib presenting with acute myeloid leukemia (AML) bearing monosomy 7 and translocation t(3;8)(q26;q24) after 14 years of treatment with granulocyte colony-stimulating factor (G-CSF): A case report. J Med Case Reports 2008; 2: 319.
31. Shimamura A. Shwachman-Diamond syndrome. Semin Hematol 2006; 43: 178-188.
32. Smith MA, Smith JG. Clinical experience with the use of rhG-CSF in secondary autoimmune neutropenia. Clin Lab Haematol 2002; 24: 93-97.
33. Welte K, Dale D. Pathophysiology and treatment of severe chronic neutropenia. Ann Hematol 1996; 72: 158-165.
34. Freedman MH. Safety of long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia. Curr Opin Hematol 1997; 4: 217-224.
35. Ancliff PJ. Congenital neutropenia. Blood Rev 2003; 17: 209-216.
36. Carlsson G, Aprikyan AA, Ericson KG, et al. Neutrophil elastase and granulocyte colony-stimulating factor receptor mutation analyses and leukemia evolution in severe congenital neutropenia patients belonging to the original Kostmann family in northern Sweden. Haematologica 2006; 91: 589-595.
37. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107: 4628-4635.
38. Bellanne-Chantelot C, Clauin S, Leblanc T, et al. Mutations in the ELA2 gene correlate with more severe expression of neutropenia: A study of 81 patients from the French Neutropenia Register. Blood 2004; 103: 4119-4125.
39. Cassinat B, Bellanne-Chantelot C, Notz-Carrere A, et al. Screening for G-CSF receptor mutations in patients with secondary myeloid or lymphoid transformation of severe congenital neutropenia. A report from the French neutropenia register. Leukemia 2004; 18: 1553-1555.
40. Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. Blood 2007; 109: 93-99.
41. SCNIR available at:.
42. Yakisan E, Schirg E, Zeidler C, et al. High incidence of significant bone loss in patients with severe congenital neutropenia (Kostmann's syndrome). J Pediatr 1997; 131: 592-597.
43. Zeidler C, Germeshausen M, Klein C, Welte K. Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia. Br J Haematol 2009; 144: 459-467.
44. Bruin MC, von dem Borne AE, Tamminga RY, et al. Neutrophil antibody specificity in different types of childhood autoimmune neutropenia. Blood 1999; 94: 1797-1802.
45. Garcia TA, Villegas MA, Gonzalez Fernandez AF. Hematological abnormalities in patients with systemic lupus erythematosus. Ann Med Intern 2002; 19: 539-543.
46. Visser G, Rake JP, Labrune P, et al. Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 2002; 161 ( Suppl 1): S83-S87.
47. Cabrera-Abreu J, Crabtree NJ, Elias E, et al. Bone mineral density and markers of bone turnover in patients with glycogen storage disease types I, III and IX. J Inherit Metab Dis 2004; 27: 1-9.
48. Ebihara Y, Manabe A, Tsuruta T, et al. The effect of donor leukocyte infusion on refractory pure red blood cell aplasia after allogeneic stem cell transplantation in a patient with myelodysplastic syndrome developing from Kostmann syndrome. Int J Hematol 2007; 86: 446-450.
49. Fukano R, Nagatoshi Y, Shinkoda Y, et al. Unrelated bone marrow transplantation using a reduced-intensity conditioning regimen for the treatment of Kostmann syndrome. Bone Marrow Transplant 2006; 38: 635-636.
50. Sakata N, Kawa K, Kato K, et al. Unrelated donor marrow transplantation for congenital immunodeficiency and metabolic disease: An update of the experience of the Japan Marrow Donor Program. Int J Hematol 2004; 80: 174-182.
51. Myers SN, Zeevi A, Zorich GP, et al. Successful engraftment following unrelated donor transplant in an alloimmunized patient with Kostmann syndrome. Pediatr Blood Cancer 2005; 44: 508-510.
52. Choi SW, Boxer LA, Pulsipher MA, et al. Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. Bone Marrow Transplant 2005; 35: 473-477.
53. Ferry C, Ouachee M, Leblanc T, et al. Hematopoietic stem cell transplantation in severe congenital neutropenia: Experience of the French SCN register. Bone Marrow Transplant 2005; 35: 45-50.
54. Nakazawa Y, Sakashita K, Kinoshita M, et al. Successful unrelated cord blood transplantation using a reduced-intensity conditioning regimen in a 6-month-old infant with congenital neutropenia complicated by severe pneumonia. Int J Hematol 2004; 80: 287-290.
55. Mino E, Kobayashi R, Yoshida M, et al. Umbilical cord blood stem cell transplantation from unrelated HLA-matched donor in an infant with severe congenital neutropenia. Bone Marrow Transplant 2004; 33: 969-971.
56. Zeidler C, Welte K, Barak Y, et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood 2000; 95: 1195-1198.
57. Carlsson G, Winiarski J, Ljungman P, et al. Hematopoietic stem cell transplantation in severe congenital neutropenia. Pediatr Blood Cancer 2011; 56: 444-451.
58. Oshima K, Hanada R, Kobayashi R, et al. Hematopoietic stem cell transplantation in patients with severe congenital neutropenia: An analysis of 18 Japanese cases. Pediatr Transplant 2010; 14: 657-663.
59. Germeshausen M, Skokowa J, Ballmaier M, et al. G-CSF receptor mutations in patients with congenital neutropenia. Curr Opin Hematol 2008; 15: 332-337.